Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Enrico Agabiti-Rosei, Enzo Porteri & Damiano Rizzoni. (2009) Arterial stiffness, hypertension, and rational use of nebivolol. Vascular Health and Risk Management 5, pages 353-360.
Read now
Read now
André C Schmidt, Burkhard Flick, Elke Jahn & Peter Bramlage. (2008) Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers. Vascular Health and Risk Management 4:4, pages 909-915.
Read now
Read now
Rudolf A de Boer, Adriaan A Voors & Dirk J van Veldhuisen. (2007) Nebivolol: third-generation β-blockade. Expert Opinion on Pharmacotherapy 8:10, pages 1539-1550.
Read now
Read now
Articles from other publishers (29)
Yeliz İpek & Berna Koçak. (2023) Novel electrochemical sensor of nebivolol drug used for treatment of hypertension and chronic heart failure. Chemical Papers 77:5, pages 2783-2792.
Crossref
Crossref
Serap Otçu, Engin Deveci, Çağdaş Özgökçe, Görkem Tutal Gürsoy & Mehmet Cudi Tuncer. (2023) Protective effect of nebivolol on rat ovary exposed to deltamethrin toxicity. Acta Cirúrgica Brasileira 38.
Crossref
Crossref
Lara Marques, Bárbara Costa & Nuno Vale. (2022) New Data for Nebivolol after In Silico PK Study: Focus on Young Patients and Dosage Regimen. Pharmaceutics 14:9, pages 1911.
Crossref
Crossref
Yi-Bang Cheng & Ji-Guang Wang. 2022. Textbook of Arterial Stiffness and Pulsatile Hemodynamics in Health and Disease. Textbook of Arterial Stiffness and Pulsatile Hemodynamics in Health and Disease
783
793
.
Umesh Ingle & Arvind Lali. (2020) Preparative separation of nebivolol isomers by improved throughput reverse phase tandem two column chromatography. Chirality 32:11, pages 1324-1335.
Crossref
Crossref
Melike Hacer Ozkan & Serdar Uma. (2018)
β-adrenergic Receptor Blocker ICI 118,551 Selectively Increases Intermediate-Conductance Calcium-Activated Potassium Channel (IK
Ca
)-Mediated Relaxations in Rat Main Mesenteric Artery
. Basic & Clinical Pharmacology & Toxicology 122:6, pages 570-576.
Crossref
Crossref
Erim Gulcan, Demet Ilhan & Serdar Toker. (2016) Nebivolol Might Be Beneficial in the Prevention and Treatment of Diabetic Neuropathy. American Journal of Therapeutics 23:1, pages e240.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
201
214
.
Philip Wai Hong Chan, Wan Teng Teo, Shaun Wei Yong Koh, Bo Ra Lee, Benjamin James Ayers, Dik-Lung Ma & Chung-Hang Leung. (2015)
Silver Triflate Catalyzed Cyclopropyl Carbinol Rearrangement for Benzo[
b
]oxepine and 2
H
-Chromene Synthesis
. European Journal of Organic Chemistry 2015:20, pages 4447-4456.
Crossref
Crossref
Ramiro J. Zepeda, Rodrigo Castillo, Ramón Rodrigo, Juan C. Prieto, Ivonne Aramburu, Solange Brugere, Katia Galdames, Viviana Noriega & Hugo F. Miranda. (2012) Effect of Carvedilol and Nebivolol on Oxidative Stress‐related Parameters and Endothelial Function in Patients with Essential Hypertension. Basic & Clinical Pharmacology & Toxicology 111:5, pages 309-316.
Crossref
Crossref
Ming-Guo Feng, Minolfa C. Prieto & L. Gabriel Navar. (2012)
Nebivolol-induced vasodilation of renal afferent arterioles involves β
3
-adrenergic receptor and nitric oxide synthase activation
. American Journal of Physiology-Renal Physiology 303:5, pages F775-F782.
Crossref
Crossref
Charles Lindamood, Stephan Ortiz, Andrew Shaw, Russ Rackley & J. Christopher Gorski. (2011) Effects of Commonly Administered Agents and Genetics on Nebivolol Pharmacokinetics: Drug-Drug Interaction Studies. The Journal of Clinical Pharmacology 51:4, pages 575-585.
Crossref
Crossref
Rebecca L Stone, Anil K Sood & Robert L Coleman. (2010) Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. The Lancet Oncology 11:5, pages 465-475.
Crossref
Crossref
Beste Ozben, Evrim Dursun, Emanuela Monari, Aurora Cuoghi, Stefania Bergamini, Aldo Tomasi & Tomris Ozben. (2009) Proteomic profiling during atherosclerosis progression: Effect of nebivolol treatment. Molecular and Cellular Biochemistry 331:1-2, pages 9-17.
Crossref
Crossref
Debra W. KempJamie N. BrownToyin S. Tofade. (2009) Recent Advances in Pharmacotherapy. Journal of Pharmacy Practice 22:5, pages 446-466.
Crossref
Crossref
T. P. Pronko & V. V. Zinchuk. (2009) Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension. Clinical Physiology and Functional Imaging 29:3, pages 170-176.
Crossref
Crossref
Sabine C. Wolf, Gabriele Sauter, Jürgen Jobst, Volkard A. Kempf, Teut Risler & Bernhard R. Brehm. (2008) Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. International Journal of Cardiology 125:1, pages 4-10.
Crossref
Crossref
C. Porta, C. Paglino, I. Imarisio & L. Bonomi. (2008) Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clinical and Experimental Medicine 7:4, pages 127-134.
Crossref
Crossref
Adriana Georgescu, Doina Popov, Emanuel Dragan, Elena Dragomir & Elisabeta Badila. (2007) Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension. European Journal of Pharmacology 570:1-3, pages 149-158.
Crossref
Crossref
Jean Lefebvre, Luc Poirier, Paul Poirier, Jacques Turgeon & Yves Lacourciere. (2007) The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. British Journal of Clinical Pharmacology 63:5, pages 575-582.
Crossref
Crossref
Rudiger Schellenberg, Albert Lichtenthal, Heike Wöhling, Christine Graf & Klara Brixius. (2007) Nebivolol and Metoprolol for Treating Migraine: An Advance on ?-Blocker Treatment?. Headache: The Journal of Head and Face Pain 0:0, pages 070503104159011-???.
Crossref
Crossref
Tuomo NieminenMika Kähönen & Tiit Kööbi. (2006) Letter by Nieminen et al Regarding Article, “Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study”. Circulation 114:15.
Crossref
Crossref
Marit D Moen & Antona J Wagstaff. (2006) Nebivolol. Drugs 66:10, pages 1389-1409.
Crossref
Crossref
Andrew J S Coats. (2006) ??-Adrenoceptor Antagonists in Elderly Patients with Chronic Heart Failure. Drugs & Aging 23:2, pages 93-99.
Crossref
Crossref
Paul Vanhoutte & Michel Félétou. 2005. EDHF. EDHF
177
277
.
N.V.S. Ramakrishna, K.N. Vishwottam, M. Koteshwara, S. Manoj, M. Santosh & D.P. Varma. (2005) Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 39:5, pages 1006-1013.
Crossref
Crossref
I S Hoffmann, R Tavares-Mordwinkin, A M Castejon, A B Alfieri & L X Cubeddu. (2004) Endothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. Journal of Human Hypertension 19:3, pages 233-240.
Crossref
Crossref
Giuseppe Sacco, Stefano Evangelista, Marco Criscuoli, Cristina Goso, Mario Bigioni, Monica Binaschi, Stefano Manzini & Carlo Alberto Maggi. (2005) Involvement of nitric oxide in both central and peripheral haemodynamic effect of d/l-nebivolol and its enantiomers in rats. European Journal of Pharmacology 511:2-3, pages 167-174.
Crossref
Crossref
Ettore Ambrosioni & Claudio Borghi. (2005) Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective ??-Blockers in the Treatment of Hypertension. High Blood Pressure & Cardiovascular Prevention 12:1, pages 27-35.
Crossref
Crossref